# Cencora, Inc.: Form 10-Q for the period ended Mar 31, 2009

- Company: [Cencora, Inc.](/companies/cor.md) (CIK 1140859)
- Form: 10-Q
- Filed: 2009-05-08
- Accepted by EDGAR: May 8, 2009, 17:57 ET
- Period: 2009-03-31
- Accession: 0001362310-09-006898
- Inline XBRL: no
- Main document: https://www.sec.gov/Archives/edgar/data/1140859/000136231009006898/c85006e10vq.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1140859/000136231009006898/

## Management's discussion and analysis

As filed, 6,239 characters.

We continue to expect that our total revenue growth in fiscal 2009 will be between 1% and 3%, with ABDC growing between 0% and 2% and ABSG growing between 5% and 7% for the fiscal year. ABDC revenue growth is expected to be higher in the second-half of fiscal 2009 compared to the first-half due to the anniversary of the national retail drug chain customer loss described above and the addition of several new customers in the second half of fiscal 2009. The expected growth also reflects U.S. pharmaceutical industry conditions, including increases in prescription drug utilization, the introduction of new products, and higher branded pharmaceutical prices, offset, in part, by the increased use of lower-priced generics. Our growth has also been impacted by industry competition and changes in customer mix. Industry sales in the United States, as recently estimated by industry data firm IMS Healthcare, Inc. (“IMS”), are expected to contract between 1% and 2% in 2009 and are expected to be flat over the five-year period ending 2013 due to continued brand to generic conversions as well as the economic slowdown in the United States in 2009. IMS expects that certain sectors of the market, such as biotechnology and other specialty and generic pharmaceuticals will grow faster than the overall market. Our future revenue growth will continue to be affected by various factors such as: industry growth trends, including the likely increase in the number of generic drugs that will be available over the next few years as a result of the expiration of certain drug patents held by brand manufacturers, general economic conditions in the United States, competition within the industry, customer consolidation, changes in pharmaceutical manufacturer pricing and distribution policies and practices, increased downward pressure on reimbursement rates, and changes in Federal government rules and regulations.

Gross profit of $552.5 million in the quarter ended March 31, 2009 increased 3% from the prior year quarter. As a percentage of total revenue, gross profit in the quarter ended March 31, 2009 was 3.19%, an increase of 16 basis points from the prior year quarter. These increases were primarily due to the strong growth and increased profitability of our generic programs (with generic revenue increasing by 11% in comparison to the prior year quarter), increased contributions from our fee-for-service agreements, and ABSG’s 8% growth at higher profit margins than ABDC. All of these positive factors combined to more than offset normal competitive pressures on customer margins in the current year quarter. Gross profit in the current year quarter benefited from a settlement of $1.8 million with a former customer. Gross profit in the prior year quarter benefited from a gain of $3.2 million relating to a favorable litigation settlement with a former customer and a $2.4 million gain resulting from a settlement of disputes that ABSG had with a vaccine manufacturer. Gross profit of $1.0 billion in the six months ended March 31, 2009 increased 2% from the prior year period. As a percentage of total revenue, gross profit in the six months ended March 31, 2009 was 3.01%, an increase of 9 basis points from the prior year period. These increases were primarily due to the strong growth and increased profitability of our generic programs, increased contributions from our fee-for-service agreements, including $10.2 million of fees relating to prior period sales due to the execution of new agreements in the quarter ended December 31, 2008, and good growth from ABSG’s businesses, all of which were partially offset by ABSG’s $12.7 million loss on its influenza vaccine program, which included a $15.5 million write-down of excess influenza vaccine inventory. The gross profit in the prior year six month period benefited from a gain of $13.2 million relating to favorable litigation settlements with a former customer and a major competitor. Additionally, in the prior year six month period, we recognized a gain of $1.6 million from antitrust litigation settlements with pharmaceutical manufacturers. This gain, which was excluded from the determination of Pharmaceutical Distribution segment’s gross profit, was recorded as reduction to cost of goods sold.

Our cost of goods sold for interim periods includes a last-in, first-out (“LIFO”) provision that is based on our estimated annual LIFO provision. We recorded a LIFO charge of $11.6 million and $9.6 million in the quarters ended March 31, 2009 and 2008, respectively. Our LIFO charge was $16.6 million and $12.7 million in the six months ended March 31, 2009 and 2008, respectively. The annual LIFO provision is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and other external influences.

Operating expenses of $304.2 million and $596.2 million in the quarter and six months ended March 31, 2009, which include facility consolidations, employee severance and other charges of $4.3 million and $5.3 million, respectively, as described below, were relatively flat in comparison to the prior year periods, despite the significant investments made in our Business Transformation project, which includes a new enterprise resource planning (“ERP”) platform. When compared to the prior year quarter and six month periods, our Business Transformation expenses increased by $9.1 million and $18.3 million, respectively. We have been able to offset these incremental costs by reducing our warehouse operating costs from continuing productivity improvements and by streamlining our organizational structures within ABDC and ABSG, as a result of our cE2 initiative described below. Operating expenses in the quarters ended March 31, 2009 and 2008 included certain asset impairment charges totaling $4.1 million and $4.7 million, respectively. As a percentage of total revenue, operating expenses were 1.76% and 1.72% in the quarter and six months ended March 31, 2009. These percentages were slightly higher than the percentages in the prior year periods due to the declines in total revenue as operating expense dollars were relatively flat compared to the prior year periods, as noted above.

## Market risk

As filed, 168 characters.

The Company’s most significant market risk is the effect of fluctuations in interest rates. See discussion under “Liquidity and Capital Resources” in Item 2 on page 31.

## Controls and procedures

As filed, 1,892 characters.

The Annual Meeting of Stockholders of the Company was held on February 19, 2009 in Philadelphia, Pennsylvania. At the meeting, the stockholders of the Company were asked to vote upon the following matters and cast their votes as set forth below.

*Election of Directors.* The three nominees each were elected to a three-year term expiring in 2012 by the following vote:

| Name | For | Against | Abstain |
| --- | ---: | ---: | ---: |
| Richard C. Gozon | 134,288,723 | 2,239,465 | 136,198 |
| Michael J. Long | 134,299,430 | 2,235,077 | 129,879 |
| J. Lawrence Wilson | 134,306,535 | 2,228,186 | 129,665 |

Directors whose term of office continued after the Annual Meeting were: Richard W. Gochnauer, Edward E. Hagenlocker, and Henry W. McGee, each of whose terms expire in 2010, and Charles H. Cotros, Jane E. Henney, M.D, and R. David Yost, each of whose terms expire in 2011.

*Independent Registered Public Accountants.* The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for fiscal 2009 was satisfied by the following vote:

| Nominee | For | Against | Abstain |
| --- | ---: | ---: | ---: |
| Ernst & Young LLP | 133,716,791 | 2,875,138 | 72,457 |

*Amendments to the AmerisourceBergen Corporation 2002 Management Incentive Plan and Approval of the Plan, As Amended.* The amendments to the AmerisourceBergen Corporation 2002 Management Incentive Plan, were approved by the following vote:

| Plan | For | Against | Abstain |
| --- | ---: | ---: | ---: |
| AmerisourceBergen Corporation 2002 Management Incentive Plan | 105,916,381 | 18,949,170 | 236,044 |

*AmerisourceBergen Poison Pill.* The stockholder proposal to redeem the Company’s poison pill was approved by the following vote:

| Item | For | Against | Abstain |
| --- | ---: | ---: | ---: |
| Stockholder Proposal to Redeem Poison Pill | 99,055,839 | 25,820,935 | 2,248,231 |

## Risk factors

As filed, 2,698 characters.

The Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2008 included a detailed discussion of our risk factors under Part I, “Item 1A — Risk Factors.” The information presented below sets forth material changes from the risk factors described in the 2008 Form 10-K and should be read in conjunction with the risk factors and information described in the 2008 Form 10-K and the Company’s filings with the SEC since the date of the 2008 Form 10-K.

*Changes to the United States healthcare environment, including the impact of measures to finance reforms, may negatively impact our business and our profitability.*

Our products and services are intended to function within the structure of the healthcare financing and reimbursement system currently existing in the United States. In recent years, the healthcare industry has undergone significant changes in an effort to reduce costs and government spending. These changes include an increased reliance on managed care; cuts in certain Medicare funding affecting our healthcare provider customer base; consolidation of competitors, suppliers and customers; and the development of large, sophisticated purchasing groups. We expect the healthcare industry to continue to change significantly in the future. Some of these potential changes, such as a reduction in governmental funding for certain healthcare services or adverse changes in legislation or regulations governing prescription drug pricing, healthcare services or mandated benefits, may cause healthcare industry participants to reduce the amount of our products and services they purchase or the price they are willing to pay for our products and services. We expect continued government and private payor pressure to reduce pharmaceutical pricing. Changes in pharmaceutical manufacturers’ pricing or distribution policies could also significantly reduce our profitability.

President Obama’s proposed fiscal year 2010 budget, which was released on February 26, 2009, contains a number of proposed Medicare and Medicaid policy changes as well as measures designed to finance comprehensive health care reform, such as health system savings and tax increases. One of the mechanisms proposed to increase taxes is the elimination of the last-in, first-out (LIFO) inventory method of accounting, which we currently use. Many of the proposed policy changes would require Congressional approval to implement. There can be no assurances that future revisions to Medicare or Medicaid policy changes or the impact of measures to finance reform, if enacted, will not have a material adverse effect on our business, financial condition, cash flows and results of operations.

Filed May 8, 2009.
Source: SEC EDGAR, the filing index for accession 0001362310-09-006898. Last ingested by Listed: Nov 15, 2026, 01:23 ET. No prices; not investment advice.
